On March 02, Ampio Pharmaceuticals Inc. (AMPE) announced positive data from Phase 3 clinical trial of AmpionTM in severe osteoarthritis of the knee (OAK). Consequently,
Shares of Ampio Pharmaceuticals Inc. (AMPE) were last seen at $2.08 in premarket trading, up 15.56%. Ampio stock closed last session at $1.80, gaining 1.12%,
This year, biotech companies on the stock exchange have skyrocketed. This is no surprise since biotech firms are the leaders in the battle against the
NanoVibronix Inc. (NASDAQ: NAOV) shares are trading down -4.55% at $1.05 at the time of writing after announcing $6.0 million private placement. Company’s 52-week ranged
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.